The Motley Fool

Why Pharmaxis is down 45%

Shares of pharmaceutical and biotech company Pharmaxis (ASX: PXS) are down nearly 50% today — and down nearly 87% year to date, compared to a near 10% rise in the S&P/ASX 200 index (Index: ^AXJO) (ASX: XJO). What’s behind this jaw-dropping plunge?

Screen Shot 2013-04-24 at 2.03.50 PM

It seems the drop is down to disappointing results from a late-stage trial of the company’s Bronchitol drug. As The Australian has reported, “Pharmaxis said its Phase III clinical trial of Bronchitol, also referred to as B305, had not shown a significant difference in the rates of pulmonary exacerbations (worsening lung function) in patients treated over a 12-month period.”

Shares were halted following the company’s receiving the news this past Monday, delaying the ugly result until today, when trading resumed.

Chief executive of Pharmaxis Gary Phillips has said that “It is disappointing not to have achieved the primary endpoint in this trial… We will, therefore, not be proceeding immediately with a regulatory submission for bronchiectasis.”

Looking for a far more solid investment ideas? Two of Australia’s most promising small companies are still flying under the radar. Discover these two exciting ASX investments in our brand-new special FREE report, “2 Small Cap Superstars”. Click here now, it’s free!

More reading

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Catherine Baab-Muguira does not own shares in any of the companies mentioned in this article.

 

 

 

 

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!